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ABSTRACT
Objectives: Cardiac magnetic resonance (CMR) imaging is very pertinent in the diagnosis and risk stratification
of patients with hypertrophic cardiomyopathy (HCM). We aimed to assess the patterns of left ventricular (LV)
hypertrophy, late gadolinium enhancement (LGE), and their prognostic significance in HCM patients in Pakistani
population, as no such data are available from Pakistan.
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Material and Methods: This was a retrospective, single center study. All patients who had confirmed diagnosis
of HCM on CMR at Aga Khan University Hospital during the period of 2011–2019 were identified and included
in the study.
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Results: A total of 74 patients were included with the mean age of 45.6 ± 15 years and the majority 71.6 % (n = 53)
being male. Maximal LV wall thickness was 21.1 ± 5 mm, asymmetrical septal hypertrophy being the most
common pattern (62.2%, n = 46). LGE was present in 75.7% (n = 56) with most common site being septum plus
LV free wall (24.3%, n =18). Mean ejection fraction% was found to be lower in patients with LGE (P < 0.001).
Major adverse cardiac events (MACE) were observed in 40.5% (n = 30). Presence of LGE and right ventricular
involvement was found to have a statistically significant association with MACE (P value 0.018 and 0.046,
respectively). In multivariable analysis, only LGE was significantly associated with MACE (odd ratio: 4.65; 95%
CI: 1.21–17.88).
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Conclusion: Asymmetrical septal hypertrophy was the most common pattern of hypertrophy. LGE was present in
three fourth of the study population and it was significantly associated with MACE.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death (SCD)
in young people worldwide. It is a genetic cardiac disease with a heterogeneous phenotypic
expression caused by autosomal dominant mutations in contractile sarcomeric proteins. It has a
prevalence of 1:500 in general population.[1,2]. Conventionally, it is diagnosed by the presence of
left ventricular (LV) hypertrophy on 2D-echocardiography; however, cardiac magnetic resonance
(CMR) is increasingly being used as a specific imaging modality.
is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others
to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
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CMR is more pertinent not only in the diagnosis of HCM
but also in predicting the prognosis by detection of late
gadolinium enhancement (LGE). CMR has an edge over
echocardiography as it provides more accurate assessment
of LV function and LV hypertrophy.[3] It can also accurately
detect the different patterns of LV hypertrophy, that is,
asymmetric, symmetric, apical, and mid ventricular.
Worldwide, much data are available on the patterns of
hypertrophy and LGE on CMR in HCM. However, there is
paucity of data on this topic in our population. This study was
conducted to assess the patterns of LV hypertrophy and LGE
on CMR, in HCM patients in Pakistani population. We also
determined the prognostic significance of LGE in these patients.
This is the first study of its kind in Pakistani population. As Aga
Khan University Hospital (AKUH) is the first and the only
center offering comprehensive CMR services in the country
since 2011, so this was the best place to conduct such study.

MATERIAL AND METHODS
This study was conducted after approval from the ethical
review committee. All the patients who had undergone CMR
at AKUH with the suspected diagnosis of HCM, during the
period 2011 to 2019 were identified using Health Information
Management Services. Only those patients were included in
the study who had confirmed diagnosis of HCM on CMR.
A pre-designed data entry form was filled for each patient
after reviewing their medical records. Information
was collected regarding age, gender, clinical features at
presentation, Electrocardiogram (EKG) findings, echo
data, and CMR findings. Follow-up data regarding death,
arrhythmias and hospital admissions for heart failure were
also collected by reviewing the medical records.
HCM
The diagnosis of HCM was based on the CMR demonstration
of a hypertrophied LV (wall thickness ≥15 mm), with a nondilated cavity in the absence of another cardiac or systemic
disease that could produce the magnitude of hypertrophy
evident.
Exclusion criteria
Patients with the diagnosis of cardiac amyloidosis, Fabry’s
disease, or cardiac sarcoidosis were excluded from the study.
Similarly, patients with LV hypertrophy due to hypertension,
aortic stenosis, or athlete’s heart were excluded from the study.
CMR data acquisition
CMR was performed using a 1.5T Siemens Avanto scanner.
A breath hold steady-state free-precession ECG-triggered
Journal of Clinical Imaging Science • 2021 • 11(14)
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sequence was used to evaluate global LV and right ventricular
(RV) function. In each patient, two long axis views (one
vertical and one horizontal) and two LVOT views were
acquired. A set of contiguous short-axis views were also
acquired from the mitral plane to the apex with the following
parameters: Slice thickness 7 mm, distance factor 25%,
field of view 34 cm, matrix 192 × 192, flip angle 80, TR/TE
58.74/1.12, and bandwidth 930 hz/px.
LGE images were obtained 8–10 min after bolus injection
of gadolinium. Images were acquired in the same views as
used for cine CMR. The inversion time was optimized to null
signal from the normal myocardium.
CMR analysis
All the images were analyzed by a reader who was qualified
and experienced in cardiovascular imaging. The analysis of
CMR images was done on third party software – Medis Q
mass. The endocardial and epicardial borders were drawn
manually on the series of short axis cine slices of the LV at
end-diastole and end-systole to obtain end-diastolic volume
and end-systolic volume, respectively. The LV ejection
fraction (EF) was calculated from the EDV and ESV, and
presented as percentages to EDV.
LGE analysis was done visually; all tomographic short axis
LV slices from base to apex were inspected to identify LGE.
In addition, two chamber, four chamber, three chamber, and
LVOT views were also inspected for identification of LGE
visually.
RV involvement was considered when RV free wall thickness
was >5 mm. Maximal LV wall thicknesses were defined as the
greatest dimension anywhere within the LV myocardium.
No definite cutoff for mild, moderate, and severe LV wall
thickness/hypertrophy is available for CMR. We just
took the echocardiographic cutoff values which are: Mild
hypertrophy – male 11–13 mm, female 10–12 mm; moderate
hypertrophy – male 14–16 mm, female 13–15 mm; and
severe hypertrophy – male >16 mm, female >15 mm.
LVOT and mid cavity obstruction was assessed visually.
Similarly, no quantification was done for assessment of
severity of mitral regurgitation.
Follow-up
Follow-up clinical events were recorded by review of hospital
records of clinic visits, hospital admissions, and telephonic
interviews with the patient or a family member, in case the
patient was unavailable. The clinical events considered were
death, hospital admissions for heart failure, life-threatening
arrhythmias, and appropriate Implantable Cardioverter
Defibrillator (ICD) discharges. All deaths were presumed
to be cardiac deaths unless a clear non-cardiac cause could
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be established. Life-threatening arrhythmia was defined as
documented ventricular tachycardia (VT) or ventricular
fibrillation (VF) by EKG strips or ICD interrogation.
Statistical analysis
Data were entered and analyzed using the Statistical Package
for the Social Sciences, version 24.0. Quantitative variables
were expressed as mean and standard deviation or median
(interquartile ranges) as appropriate. Qualitative variables
were expressed as absolute frequencies and percentages.
Qualitative data were compared using the two test or Fisher’s
exact test, as appropriate. Continuous data were compared
using an independent samples t test or the Mann-Whitney
U-test, depending on their distribution. A two-sided P < 0.05
was considered statistically significant for all tests.

A total of 74 patients who fulfilled the inclusion criteria were
included in the study. Baseline clinical and demographic
characteristics are summarized in Table 1. Mean age was
45.6 ± 15 years with the majority 71.6 % (n = 53) being
male. Dyspnea (62.2%, n = 46) was the main symptom at
presentation, followed by syncope (39.2%, n = 29).
Findings of CMR are shown in Table 2. Maximal LV wall
thickness was 21.1 ± 5 mm with more than half of patients
56.8% (n = 42) having severe LV hypertrophy. Asymmetrical
septal hypertrophy was the most common pattern of
hypertrophy present in 62.2% (n = 46) of the patients,
followed by septal and anterior wall hypertrophy (17.6%,
n = 13). Various patterns of LV hypertrophy are shown in
Figures 1-5.
LGE was present in 75.7% (n = 56) of the patients
[Figures 6 and 7] and most common site was septum plus
LV free wall (32.1%, n = 18), followed by apical site (17.8%,
Table 1: Clinical and demographic characteristics.
Age mean±SD
Male
Hypertension
Diabetes
Dyslipidemia
Family history of sudden
cardiac death
Family history of hypertrophic
cardiomyopathy
Symptoms at presentation
Dyspnea
Syncope
Palpitations
Chest pain

Patients were divided into two groups on the basis of presence
or absence of LGE [Table 3]. There was no statistically
significant difference between two groups on basis of age and
gender. However, patients with LGE were more likely to have
systolic dysfunction (P = 0.018) and mean EF was also found
to be lower in patients with LGE (P < 0.001). Maximal LV wall
thickness and mean LV mass was also greater in patients with
LGE (P = 0.001 and 0.016) compared to those without LGE.
Follow-up was available in all patients and mean follow-up
duration was 39.6 + 27.3 months. Major adverse cardiac
events (MACE) (Death, heart failure, VT/VF) were observed
in 40.5% (30/74) of the study population [Table 4].
Table 2: CMR findings in patients with hypertrophic
cardiomyopathy.

RESULTS

Characteristics

n = 10). Most common pattern of LGE was patchy which was
present in 73.2% (n = 41).

Number (n=74)

Percentage

45.6±15
53
28
8
1
23

‑
71.6
37.8
10.8
1.4
31.1

12

16.2

46
29
25
16

62.2
39.2
33.8
21.6

CMR findings
Mean EF
>60%
51–59%
<50%
Maximal LV thickness (mm)
Mild
Moderate
Severe
Pattern of hypertrophy
Asymmetrical septal
hypertrophy
Septum and anterior wall
Symmetric
Mid Ventricular
Apical
RV involvement
Increased LV Mass
LVOT obstruction
Mid‑cavity obstruction
Systolic anterior motion
Mitral regurgitation
LGE
Site of LGE
Septum+LV free wall
Apex
Septum
Multifocal
LV free wall
RV insertion site
Pattern of LGE
Patchy
Focal
Transmural
Diffuse
Sub‑endocardial

Number (n=74)

Percentage

67.8±2
62
5
7
21.1±5
6
26
42

83.8
6.8
9.5
8.1
35.1
56.8

46

62.2

13
5
5
5
12
57
21
12
23
18
56
(n=56)
18
10
8
8
7
5

17.6
6.8
6.8
6.8
16.2
77
28.4
16.2
31.1
24.3
75.7
32.1
17.85
14.28
14.28
12.5
8.92

41
8
4
2
1

73.21
14.28
7.14
3.57
1.78

CMR: Cardiac magnetic resonance, LV: Left ventricle, RV: Right ventricle,
LGE: Late gadolinium enhancement
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Figure 1: A 70-year old male with hypertension presented with
history of syncope. Cardiac magnetic resonance steady-state free
precession still frame 3chamber view showing asymmetrical septal
hypertrophy (arrow).

Figure 2: A 55-year old male with history of palpitation and left
ventricular hypertrophy on echo. Cardiac magnetic resonance
steady-state free precession still frame short axis view showing
septal and anterior wall hypertrophy (arrow).

Patients were divided into two groups on the basis of presence
or absence of MACE [Table 5]. The presence of LGE and
RV involvement was found to have a statistically significant
association with MACE. In multivariable analysis, only LGE
was significantly associated with MACE (odd ratio: 4.65; 95%
CI: 1.21–17.88).

DISCUSSION
This is the first study of its kind from this part of the world,
describing the patterns of LV hypertrophy and LGE in
patients with HCM on CMR, and looking at their prognostic
Journal of Clinical Imaging Science • 2021 • 11(14)
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Figure 3: A 71-year old male with history of syncope. Cardiac
magnetic resonance steady-state free precession still frame
2chamber view showing mid ventricular hypertrophy (arrow).

Figure 4: A 38-year old male with history of chest pain, diffuse T
wave changes on ECG and normal coronary angiogram. Cardiac
magnetic resonance steady-state free precession still frame
2chamber view showing apical hypertrophy (arrow).

significance. This will highlight the importance of CMR in
the diagnosis and management of HCM in our population.
CMR plays a pivotal role in the diagnosis and risk stratification
of patients with HCM. Due to high resolution, CMR
determines the LV wall thickness accurately, compared to
echocardiography. There are multiple morphological variants
of HCM which are easily recognized by CMR. Asymmetrical
septal hypertrophy was the most common morphologic
presentation of HCM in our series. In this variant
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a

b

Figure 7: A 50-year old male with history of palpitation and
syncope. (a) Cardiac magnetic resonance late gadolinium image
2chamber view showing hyper-enhancement in the anterior wall
(arrow). (b) Cardiac magnetic resonance late gadolinium image
short axis view showing hyper-enhancement in the anterior wall
and adjacent septum (arrow).
Table 3: Comparison of patients with and without LGE.
Figure 5: A 49-year old female with history of shortness of breath
and left ventricular hypertrophy but no hypertension or aortic
stenosis. Cardiac magnetic resonance steady-state free precession
still frame 4chamber view showing symmetrical hypertrophy
(arrow).

Age
Gender
Male
Female
Mean LV mass (g)
LV wall thickness
EF Mean
EF
>60%
51–59%
<50%
LVOT obstruction

LGE+

LGE−

P‑value

(44±16)

(48.3±14.7)

0.43

43 (81.1%)
13 (61.9%)
(231±99)
(22.3±5.4)
62.7±14.1

10 (18.9%)
1 (38.1%)
(175±40)
(17.5±2)
74.05±5.3

0.08

43 (71%)
5 (100%)
8 (100%)
10 (47.6%)

18 (29%)
0 (0%)
0 (0%)
11 (52.4%)

0.016
0.001
<0.001
0.018*
0.001

*Fischer’s exact, LGE: Late gadolinium enhancement, LV: Left ventricle,
EF: Ejection fraction

Table 4: Outcome of patients on follow‑up.
Outcomes
(Mean F/U 39.6±27.3)

Figure 6: A 71-year old male with history of syncope. Cardiac
magnetic resonance late gadolinium image showing apical hyperenhancement in mid ventricular hypertrophy variant (arrow).

hypertrophy predominantly involves the septum.[4] Septal
and anterior wall hypertrophy was the next common pattern
of hypertrophy. In this variant hypertrophy predominantly
involves the basal anterior wall and contiguous portion of the
anterior inter-ventricular septum.[4]

F/U (n=74)

Percentage

8
33
36

10.8
44.5
48.6

16
12

21.6
16.2

10
5
11
1

13.5
6.7
14.8
1.3

Mortality
ICD insertion
Hospitalization
Causes of hospitalization
Heart Failure
Ventricular
Tachycardia/
Ventricular Fibrillation
Syncope
Angina
ICD discharge
Sudden cardiac death
ICD: Implantable cardioverter defibrillator

These findings are consistent with the findings in the
literature, asymmetric HCM or septal HCM is the most
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Table 5: Association of MACE with demographic and CMR
findings.

LVEF
LV Mass
Age
LV Thickness
LGE+
LGE−
RV Involvement (+)
RV Involvement (−)
LVOT+
LVOT−

MACE+
(30/74)

MACE−
(44/74)

P‑value

63.9±14.6
220.9±95.7
42.8±17.5
22.4±5.5
27 (48.2%)
3 (16.7%)
8 (66.7%)
22 (35.5%)
10 (47.6%)
20 (37.7%)

66.50±12.6
215.7±90.1
47.5±14.2
20.3±4.9
29 (51.8%)
15 (83.3%)
4 (33.3%)
40 (64.5%)
11 (52.4%)
33 (62.3%)

0.42
0.81
0.21
0.09
0.018
0.046*
0.43

MACE: Major adverse cardiac events, CMR: Cardiac magnetic resonance,
LVEF: Left ventricle ejection fraction, LV: Left ventricle, RV: Right
ventricle, LGE: Late gadolinium enhancement

common morphologic presentation accounting for about
two thirds of the spectrum.[4,5]
In mid ventricular hypertrophy variant, the hypertrophy
predominantly involves the mid segments of the left ventricle
and may result in mid ventricular obstruction.[6,7] It may be
associated with the formation of an apical aneurysm. This
variant was seen in small number of patients in our study.
In apical variant, the hypertrophy predominantly involves
the apical segments. Diagnostic criteria for apical HCM
include an absolute apical wall thickness of >15 mm or a
ratio comparing apical LV and basal LV wall thicknesses of
≥1.3–1.5.[8,9] Apical HCM also called “Yamaguchi syndrome”
is a relatively uncommon form of HCM. This variant is more
frequent in the Japanese population. In this condition, there
is obliteration of LV cavity at the apex, giving a characteristic
spade-like configuration. In our study, apical variant was
found in 6.8% (n = 5), which is a little higher than the figures
reported from western countries (~2%) but significantly
lower than that of Japan (~25%).[4,8]

et al.,[15] and 68.9% by Klopotowski et al.[16] There are only
few studies on the Asian population and, to the best of our
knowledge, no data are available on LGE in sub-continental
South Asian HCM population. LGE was observed in 73%
of study population in Japan by Hen et al.[17] Choi et al.[18]
reported a significantly higher detection of LGE in 91.5% of
study population in South Korea. The pooled prevalence of
LGE was found to be 60% in a meta-analysis of four studies
which evaluated 1063 patients.[19] The variable prevalence can
be explained by the different study population, study designs,
inter-observer variability, and LGE detection methods.
Most common location for LGE in our study was septum and
LV free wall, which was also observed in studies by Maron
et al. and Olivotto et al.[11,20] However, apex was the most
common site in a study by Hen et al. in Japanese cohort.[17]
Severity of hypertrophy showed statistically significant
association with the presence of LGE in our study, which
is in agreement with the findings of studies by Ismail et al.
and others.[11,15,20] Our study found a statistically significant
association between LGE and LVOT obstruction, in contrast
no such association was found by Maron et al.[11] Association of
LGE with systolic dysfunction and lower EF was reported in the
studies,[11,14,15] and similar findings were observed in our study.
A high rate of MACE was observed in our study population,
which is similar to what Songsirisuk et al.[21] observed.
Cardiovascular complications were reported in 47% of
Chinese HOCM population by Ho et al.[22] and in 35.6%
by Lee et al.[23] in Taiwan. However, in contrast lower rate
was reported by studies in Europe and USA.[13,24,25] These
differences are probably due to the heterogeneous population,
variable definition of MACE, rate of ICD insertion, and
health-care resources. MACE were more common in patients
with LGE, presence of LGE has been found to increase the
risk of SCD, cardiovascular complications, and increase in
all-cause mortality.[26,27]

In the variant with symmetrical hypertrophy, the
hypertrophy involves the ventricular wall symmetrically with
no regional preferences. LV cavity dimensions are reduced
in a concentric fashion.[7,10] This entity should be evaluated
closely to differentiate it from other causes of symmetric LV
thickening.

The prevalence of RV involvement is 16.2% in our study which
is similar to 18% reported in the literature.[4,7] This typically
involves the mid-to-apical portion of the RV. RV involvement
was also found to be associated with cardiovascular
complications in our study and this was in agreement
with various other studies,[28,29] in which RV involvement
was associated with increased risk of sudden death and
ventricular arrhythmias.

On contrast enhanced CMR, areas of LGE can also be
detected, which are considered to represent areas of fibrosis.
Identification of fibrosis by LGE technique has prognostic
significance in predicting adverse clinical outcomes. In our
study, LGE was present in 75.7% cases, which is little higher
than the figures reported in the literature. LGE was reported
in 55% by Maron et al.,[11] 42% by Chan et al.,[12] 63% by
O’Hanlon et al.,[13] 68% by Lyon et al.,[14] 66.2% by Ismail

LVOT obstruction was also associated with MACE[22] and
was a strong, independent predictor of progression to severe
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LVOT obstruction was present in 28.4% of the patients in our
study, which is comparable to that found in the studies done by
Songsirisuk et al. (24%) and Maron et al. (25%).[21,30] However,
in a study done by Lee et al. on Taiwanese population, LVOT
obstruction was demonstrated in a much higher percentage
(48.1%) of HCM patients.[23]
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symptoms of heart failure and death[30] in studies done by Ho
et al. and Maron et al., respectively, which was not the case in
our study group.
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